Sepsis Therapeutics - Global Strategic Business Report

Report
291 Pages
March 2024
Region: Global
Global Industry Analysts, Inc
ID: 1882061

The global market for Sepsis Therapeutics is estimated at US$4.6 Billion in 2023 and is projected to reach US$7.1 Billion by 2030, growing at a CAGR of 5.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Cephalosporin segment, which is expected to reach US$3 Billion by 2030 with a CAGR of 5.9%. The Glycopeptide Antibiotics segment is also set to grow at 5.4% CAGR over the next 8 years.
Regional Analysis: Gain insights into the U.S. market, estimated at $1.5 Billion in 2023, and China, forecasted to grow at an impressive 7.3% CAGR to reach $776.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Sepsis Therapeutics Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Sepsis Therapeutics Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Sepsis Therapeutics Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as Adrenomed AG, AM-Pharma B.V., Asahi Kasei Pharma America, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 45 Featured):

Adrenomed AG
AM-Pharma B.V.
Asahi Kasei Pharma America
Endacea, Inc.
F. Hoffmann-La Roche Ltd.
GSK Plc
InflaRx N.V.
Inotrem SA
La Jolla Pharmaceutical Company
TaiRx, Inc.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Sepsis: A Life-Threatening Condition Requiring Urgent Action
Interventions for Managing Sepsis
Treatments that are Commonly Applied for Sepsis
Global Economic Update
Competitive Landscape
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
Global Market Prospects and Outlook
Thriving Global Sepsis Therapeutics Market Oozes Signs of Robust Health
Cephalosporins Hold a Major Share of the Treatment Market
Global Sepsis Therapeutics Market Receives Pulsating Impetus from North America, Asia-Pacific to Witness Fastest Growth
Limited Therapeutic Options: A Challenge
Antibiotics and Vasopressors - The Current Standard of Care
Current Categories of Antibacterial Agents for First-line Sepsis Treatment
Current Anti-bacterial Drugs used in Sepsis
Current Antifungals used for Sepsis
GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment
Promising Treatment for Sepsis
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Incidence of Sepsis Propels Market Growth
Aging Population: A Key Growth Driver for Sepsis Therapeutics
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
A Market Characterized by High Unmet Medical Needs
Novel Immune-Specific Modes of Action under Focus
Emphasizing on Endothelial Cell Function
HMGB1- A Potential Target for Future Therapies
Hydrocortisone Displays Potential in Septic Shock Treatment
Reduced Levels of Vitamin C Characterize Sepsis Patients
Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate
Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market
Anticancer Drugs - Offering Potential Treatment of Sepsis
New Protein to be Effective for Sepsis
Rise in Healthcare Expenditure to Drive Growth
World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
AI-Driven Sepsis Screening Approach to Save Lives
Increasing R&D Activity & New Product Launches Spur Market Growth
Purdue Researchers Develop IV Injection for Sepsis
PLK1-mTOR Axis - A Potential Therapeutic for Sepsis
New Nanoparticles - A Revolution in the Development of Clinical Sepsis Therapy
Strong Pipeline and Increased Research Activity Enables Increased Awareness of Disease Pathogenesis

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Sepsis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 3: World Historic Review for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 4: World 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
Table 5: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 6: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 7: World 16-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 8: World Recent Past, Current & Future Analysis for Glycopeptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 9: World Historic Review for Glycopeptide Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 10: World 16-Year Perspective for Glycopeptide Antibiotics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 11: World Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 12: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 13: World 16-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 17: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 18: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 19: World 16-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 23: USA Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 24: USA Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 25: USA 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 26: USA Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 27: USA Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 28: USA 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

CANADA

Table 29: Canada Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 30: Canada Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 31: Canada 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 32: Canada Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 33: Canada Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 34: Canada 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

JAPAN

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 35: Japan Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 36: Japan Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 37: Japan 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 38: Japan Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 39: Japan Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 40: Japan 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

CHINA

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 41: China Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 42: China Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 43: China 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 44: China Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 45: China Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 46: China 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

EUROPE

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 47: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 48: Europe Historic Review for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 49: Europe 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 50: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 51: Europe Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 52: Europe 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 53: Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 54: Europe Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 55: Europe 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

FRANCE

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 56: France Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 57: France Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 58: France 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 59: France Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 60: France Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 61: France 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

GERMANY

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 62: Germany Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 63: Germany Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 64: Germany 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 65: Germany Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 66: Germany Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 67: Germany 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

ITALY

Table 68: Italy Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 69: Italy Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 70: Italy 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 71: Italy Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 72: Italy Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 73: Italy 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

UNITED KINGDOM

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 74: UK Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 75: UK Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 76: UK 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 77: UK Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 78: UK Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 79: UK 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

SPAIN

Table 80: Spain Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 81: Spain Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 82: Spain 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 83: Spain Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 84: Spain Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 85: Spain 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

RUSSIA

Table 86: Russia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 87: Russia Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 88: Russia 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 89: Russia Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 90: Russia Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 91: Russia 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 92: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 93: Rest of Europe Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 94: Rest of Europe 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 95: Rest of Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 96: Rest of Europe Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 97: Rest of Europe 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 99: Asia-Pacific Historic Review for Sepsis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 100: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 102: Asia-Pacific Historic Review for Sepsis Therapeutics by Drug Class - Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 103: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Cephalosporin, Glycopeptide Antibiotics, Aminoglycosides and Other Drug Classes for the Years 2014, 2024 & 2030
Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 105: Asia-Pacific Historic Review for Sepsis Therapeutics by Route Of Administration - Intravenous and Oral Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 106: Asia-Pacific 16-Year Perspective for Sepsis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Intravenous and Oral for the Years 2014, 2024 & 2030

AUSTRALIA

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)

INDIA

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)

SOUTH KOREAREST OF ASIA-PACIFIC

LATIN AMERICA

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)

MIDDLE EAST

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)

AFRICA

Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Adrenomed AG
AM-Pharma B.V.
Asahi Kasei Pharma America
Endacea, Inc.
F. Hoffmann-La Roche Ltd.
GSK Plc
InflaRx N.V.
Inotrem SA
La Jolla Pharmaceutical Company
TaiRx, Inc.

Table Information

Report Attribute	Details
No. of Pages	291
Published	March 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 4.6 Billion
Forecasted Market Value ( USD ) by 2030	$ 7.1 Billion
Compound Annual Growth Rate	6.4%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF

1 - 10 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5407EUR$5,600USD£4,578GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10273EUR$10,640USD£8,699GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€16220EUR$16,800USD£13,735GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 45 Featured):

MarketGlass Platform

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Global Sepsis Therapeutics Market 2024-2028

MRSA Drugs - Global Strategic Business Report

Global Acinetobacter Pneumonia Therapeutics Market Analysis & Forecast to 2024-2034

Prosthetic Joint Infection Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Sepsis - Pipeline Insight, 2024

About the Market